




CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 40 Number 5 September 2013



A Case of Stroke and Blindness

Alicia Mattia, Michael Sharma, Michael Nicolle, J. Alexander Fraser, Donald Lee, Robert Hammond

Clinical Neuropathological Conference - Can J Neurol Sci. 2013; 40: 730

Figure: Photographs of the right (A) and left (B) ocular fundi, showing diffuse "pallid" edema of the optic nerves (long arrows) and retinal edema from cilioretinal artery occlusions (short arrows). (An old and unrelated incidental chorioretinal scar is also evident in the right eye (asterisk)).

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

Richness is:

Having a vast universe to explore



You define richness. With the *Scotia Professional*® Plan, we can help with the money part. You've worked long and hard to build your career. It only makes sense to do everything you can to ensure your continued success, both professionally and personally. The Professional Plan is a fully customized banking package designed to help you build a strong, profitable business while ensuring your personal finances receive the attention they deserve. Which gives you more time to explore the universe within.

To learn more about *Scotia Professional* Plan, visit your nearest Scotiabank branch or visit scotiabank.com/professional today.

Scotia Professional Plan

You're richer
than you think:



EDITORIALS

- 623** Persistence with Cholinesterase Inhibitor Treatment in Alzheimer's Disease
Fadi Massoud
- 625** A Real-World Glimpse into the Epidemiology of ALS in Canada
Nicolas Dupré, Lawrence Korngut
- 626** Hippocampal Malrotation and Temporal Lobe Epilepsy: What is the Relationship?
Mary B. Connolly

REVIEW ARTICLES

- 628** Mechanisms Underlying Taurine Protection Against Glutamate-Induced Neurotoxicity
Hai-Bo Ye, Hai-Bo Shi, Shan-Kai Yin
- 635** Mitochondrial Depletion Syndromes in Children and Adults
Josef Finsterer, Uwe Ahting

HISTORICAL REVIEW

- 645** Unique Experiences with Intercontinental Trials in Stroke - Part II
H.J.M. Barnett, John (Jack) Coleman Laidlaw

ORIGINAL ARTICLES

- 652** Hippocampal Malrotation is Associated with Chromosome 22q11.2 Microdeletion
Danielle M. Andrade, Timo Krings, Eva W.C. Chow, Tim-Rasmus Kiehl, Anne S. Bassett
- 657** Visual Hallucinations and Cognitive Impairment in Parkinson's Disease
Hee Kyung Park, Jae Seung Kim, Ki Chun Im, Mi Jung Kim, Jae-Hong Lee, Myoung C. Lee, Juhan Kim, Sun J. Chung

- 663** Effectiveness of BoNT A in Parkinson's Disease Upper Limb Tremor Management
Fariborz Rahimi, Carina Bee, Derek Debicki, Angela C. Roberts, Priya Bapat, Mandar Jog
- 670** Discrimination of the Cognitive Profiles of MCI and Depression using the KBNA
Michelle C. E. Monette, Larry Leach
- 678** Correcting the MoCA for Education: Effect on Sensitivity
Genevieve Gagnon, Kevin T. Hansen, Sarah Woolmore-Goodwin, Iris Gutmanis, Jennie Wells, Michael Borrie, Jennifer Fogarty
- 684** Less Education Predicts Anticholinesterase Discontinuation in Dementia Patients
Solin Saleh, Andrew Kirk, Debra G. Morgan, Chandima Karunanayake
- 691** Meta-Analysis on the Association Between the TF Gene rs1049296 and AD
Yun Wang, Shunliang Xu, Zhen Liu, Chao Lai, Zhaohong Xie, Cuiping Zhao, Yan Wei, JianZhong Bi
- 698** The CNDR: Collaborating to Translate New Therapies for Canadians
Lawrence Korngut, Craig Campbell, Megan Johnston, Timothy Benstead, Angela Genge, Alex MacKenzie, Anna McCormick, Douglas Biggar, Pierre Bourque, Hannah Briemberg, Colleen O'Connell, Suzan Dojeji, Joseph Dooley, Ian Grant, Gillian Hogan, Wendy Johnston, Sanjay Kalra, Hans D. Katzberg, Jean K. Mah, Laura McAdam, Hugh J. McMillan, Michel Melanson, Kathryn Selby, Christen Shoesmith, Garth Smith, Shannon L. Venance, Joy Wee on behalf of the CNDR Investigator Network
- 705** Epidemiological Surveillance of Amyotrophic Lateral Sclerosis in Saguenay Region
Émilie Lareau-Trudel, Élizabéth Fortin, Marianne Gauthier, Sarah Lavoie, Érika Morissette, Jean Mathieu
- 710** Evaluation of a Bicycle Helmet Safety Program for Children
Michael D. Cusimano, Ahmed Faress, Wilson P. Luong, Sally Lockhart, Khizer Amin, Rhonda J. Garland, Kelly Russell
- 717** Spontaneous Blink Rates in Children During Different Types of Eye Movements
Michael S. Salman, Liumei Liu

722 Calcitonin Gene Related Peptide Gene Polymorphism in Migraine Patients

Baburhan Guldiken, Tammam Sipahi, Remziye Tekinarlan, Levent Kabayel, Hulya Ozkan, Ayhan Unlu, Bilge Eren Yamasan, Tulay Okman-Kilic, Nilda Turgut

TRANSLATIONAL NEUROSCIENCE

726 Life Experience and DNA Polymorphisms Influence the Epigenome Brain

Michael O. Poulter

CLINICAL NEUROPATHOLOGICAL CONFERENCE

728 A Case of Stroke and Blindness

Alicia Mattia, Michael Sharma, Michael Nicolle, J. Alexander Fraser, Donald Lee, Robert Hammond

NEUROIMAGING HIGHLIGHT

734 Intracardiac Migration of a Ventriculoperitoneal Shunt

Jordi Pérez-Bovet, Roser Garcia-Armengol, M^a Carme Joly Torta, Secundino Martin Ferrer

BRIEF COMMUNICATIONS

736 Preserved Drawing in a Sculptor with Dementia

Luis Fornazzari, Thom Ringer, Lee Ringer, Corinne E. Fischer

738 Acute-Onset Anterograde Amnesia Caused by Isolated Bilateral Fornix Infarction

Philippe Rizek, Stephen Pasternak, Andrew Leung, Mary E. Jenkins

740 Reversible Parkinsonian Features in Deep Cerebral Venous Sinus Thrombosis

Jayantee Kalita, Sanjeev K. Bhoi, Satish Chandra, Usha K. Misra

743 Pituitary Abscess: Review and Highlight of a Case Mimicking Pituitary Apoplexy

Godefroy Hardy St-Pierre, Sandrine de Ribaupierre, Brian W. Rotenberg, Carolyn Benson

746 Oligodendrogliomas with Abundant Refractile Eosinophilic Granular Cells

Kelvin Au, Juan Bilbao, Todd Mainprize, Michael Schwartz, Julia Keith

IN MEMORIAM

749 Peter Seland (1941-2013)

Robert G. Lee

LETTERS TO THE EDITOR

750 To the Editor - Chronic Inflammatory Demyelinating Polyneuropathy and Metastatic Melanoma

Anthony M.T. Chau, Amy Yu, Mark R. Keezer

753 To the Editor - Rigidity and HyperCKemia as Presenting Signs of Hashimoto's Encephalopathy

Bojan Rugole

754 To the Editor - Recovery from Deafness in the Contralateral Ear of Surgery in NF 2 Patient

Naif M. Alotaibi, Ziyad Makoshi, Yasser Orz

BOOKS RECEIVED/BOOKS REVIEWED 757-760

INFORMATION FOR AUTHORS A-7, A-8

CLASSIFIED ADS A-9, A-12, A-14

BOARD OF DIRECTORS A-13

2014 CNSF Congress in Beautiful Banff Alberta



Once again we have secured an outstanding hotel property as our Congress venue and host hotel. We will be at the **Fairmont Banff Springs Hotel – June 3 to June 6, 2014!**

Few hotels in the world rival the majesty, hospitality and grandeur of The Fairmont Banff Springs resort, located in the heart of Banff National Park, a UNESCO World Heritage Site. This hotel was styled after a Scottish Baronial Castle and when it opened in 1888, it marked the birthplace of tourism in the Canadian Rockies.

The Fairmont Banff Springs hotel, a National Historical Site of Canada, provides unparalleled options and unique experiences to guests, from inclusive onsite getaways to days of adventure exploring the Rockies.

For the convenience of our Congress delegates, the CNSF has reserved transportation from the Calgary International Airport directly to Banff, through Brewster Corporate Event and Management. The fee is \$40.50 per person, about the same as a taxi fare from the airport to a downtown Calgary Hotel. Enjoy the ride and Enjoy the scenery.



During your stay in our Rocky Mountains, we invite you to join your colleagues for a truly Western barbecue experience amid the majestic mountain peaks.

Just minutes from Banff at Brewster's Mountainview location we will gather 'round the indoor central bonfire for an evening of entertainment and feasting.

Transportation to and from the venue is provided.

Then, looking forward to 2015! The CNSF 50th Annual Congress!

Hope to see you all at the Fairmont Royal York Hotel in Toronto, June 9 to June 12, 2015.

Editor-in-Chief/Rédacteur en chef

Robert Chen TORONTO, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB
Mark Sadler HALIFAX, NS
Mike Poulter LONDON, ON
Serge Gauthier VERDUN, QC
Robert Hammond LONDON, ON
Mary Connolly VANCOUVER, BC

Past Editors/Anciens rédacteurs en chef

G. Bryan Young LONDON, ON
Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Comité éditorial

Jorge Burneo LONDON, ON
Richard Desbiens QUEBEC CITY, QC
David Fortin SHERBROOKE, QC
Mark Hamilton CALGARY, AB
Hans-Peter Hartung DUSSELDORF, GERMANY
Michael Hill CALGARY, AB
Alan C. Jackson WINNIPEG, MB
Daniel Keene OTTAWA, ON
James Perry TORONTO, ON
Oksana Suchowersky EDMONTON, AB
Brian Toyota VANCOUVER, BC
Brian Weinschenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

David Pelz LONDON, ON

Neuropathological Conference/Conférence sur la neuropathologie

Robert Hammond LONDON, ON

**Book Review/Critiques de livres
Reflections/Reflets**

Andrew Kirk SASKATOON, SK

**Critically Appraised Topic Summaries
(CATS)**

Jorge Burneo LONDON, ON
Mary Jenkins LONDON, ON

Editorial Review Board/Comité de lecture

Donald Brunet KINGSTON, ON
Jodie Burton CALGARY, AB
Lionel Carmant MONTREAL, QC
Colin Chalk MONTREAL, QC
K. Ming Chan EDMONTON, AB
Joseph Dooley HALIFAX, NS
Paolo Federico CALGARY, AB
Daryl Fournay SASKATOON, SK
Hannah Glass SAN FRANCISCO, CA, USA
Alan Goodridge ST. JOHN'S, NL
Ian Grant HALIFAX, NS
Alan Guberman OTTAWA, ON
John Hurlbert CALGARY, AB
Manouchehr Javidan VANCOUVER, BC
Patrick McDonald WINNIPEG, MB
Martin McKeown VANCOUVER, BC
Joseph Megyesi LONDON, ON
Vivek Mehta EDMONTON, AB
Steven Miller TORONTO, ON
Neelan Pillay CALGARY, AB
Christopher Power EDMONTON, AB
Alex Rajput SASKATOON, SK
Jean Raymond MONTREAL, QC
Gary Redekop VANCOUVER, BC
Harvey Sarnat CALGARY, AB
John Stewart VANCOUVER, BC
Jeanne Teitelbaum MONTREAL, QC
Eve Tsai OTTAWA, ON
Shannon Venance LONDON, ON
Matt Wheatley EDMONTON, AB
Jerome Yager EDMONTON, AB

Journal Staff/Effectif du journal

Dan Morin CALGARY, AB
Donna Irvin
Chief Executive Officer
Cindy Leschyshyn CALGARY, AB
Editorial Coordinator
Maggie McCallion CALGARY, AB
Designer/Production Coordinator

**Advertising representative/
Représentant de publicité**

Donna Irvin
Tel (403) 229-9544 Fax (403) 229-1661
E-mail: donna-irvin@cnsfederation.org

Printer/Imprimeur

Unicom Graphics, 4501 Manitoba Road SE
Calgary, Alberta T2G 4B9

The official journal of: / La revue officielle de :

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:
Le secrétariat des quatre associations et de la Fédération des sciences neurologiques du Canada est situé en permanence à :

7015 Macleod Trail SW, Suite 709
Calgary, Alberta, Canada T2H 2K6
CNSF (403) 229-9544 / CJNS (403) 229-9575
Fax (403) 229-1661

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals (print and online) are: C\$178.00 (Canada), C\$208.00 (US), C\$292.00 (International). Subscription rates for Institutions (print and online) are C\$198.00 (Canada), C\$228.00 (US), C\$312.00 (International). "Online Only" - C\$160.00 (Individual), C\$180.00 (Institutional). See www.cjns.org for full details including taxes. Single copies C\$35.00 each plus C\$25.00 shipping and handling. E-mail: journal@cjns.org. COPYRIGHT © 2013 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Postage paid at Calgary, Alberta.

Le Journal Canadien des Sciences Neurologiques est publié tous les deux mois. Voici les prix d'abonnement pour les personnes (imprimé et en ligne) : 178,00 \$ CA (Canada), 208,00 \$ CA (É.-U.), 292,00 \$ CA (international). Voici les prix d'abonnement pour les institutions (imprimé et en ligne) : 198,00 \$ CA (Canada), 228,00 \$ CA (É.-U.), 312,00 \$ CA (international). « En ligne seulement » 160,00 \$ CA (personnes), 180,00 \$ CA (institutions). Visiter www.cjns.org pour tous les détails incluant les taxes. Exemplaires uniques : 35,00 \$ CA l'unité, plus 25,00 \$ CA en frais de port et de manutention. Courriel : journal@cjns.org. COPYRIGHT © 2013 du THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce journal ne peut être reproduite sous quelque forme que ce soit sans la permission préalable du Journal Canadien des Sciences Neurologiques. Frais de port payés à Calgary, en Alberta.

This journal is indexed by / Cette revue est indexée par :
Adis International, ArticleFirst, BIOBASE, BioAb, BiolSci, BIOSIS Prev, Centre National de la Recherche Scientifique, CSA, CurAb, CurCont, De Gruyter Saur, E-psyche, EBSCO, Elsevier, EMBASE, FRANCIS, IBZ, Internationale Bibliographie der Rezensionen Geistes- und Sozialwissenschaftlicher Literatur, MEDLINE, MetaPress, National Library of Medicine, OCLC, PE&ON, Personal Alert, PsycFIRST, PsycINFO, PubMed, Reac, RefZh, SCI, SCOPUS, Thomson Reuters, TOCprem, VINITI RAN, Web of Science.

ISSN 0317 - 1671






joie de vivre



tripant



château

québecoriginal



North America / Canada / Québec

1 877 BONJOUR

QuebecOriginal.com

Québec

REFER YOUR PATIENTS TO LYRICA.CA



*Fictitious patient. May not be representative of all cases.

FACED WITH PAIN^{1,2*}

IN HIS STRUGGLE WITH NEUROPATHIC PAIN

Pregabalin: first-line treatment for chronic **neuropathic pain**⁴

First treatment indicated in Canada for adults for the management of pain associated with **fibromyalgia**³

Demonstrated powerful, rapid and sustained pain relief^{3,5}

In neuropathic pain (NeP): Rapid and sustained pain relief (starting at week 2 for LYRICA 150-600 mg/day, n=141; $p < 0.05$ vs. placebo, n=65) was demonstrated throughout a 12-week study in patients with DPN or PHN⁵.

Demonstrated effective in relieving pain-related sleep difficulties³

In NeP: LYRICA reduced sleep disturbances across several studies in DPN and PHN, of 8-12 weeks duration³.

Flexible dosing across all indications^{3†}

LYRICA (pregabalin) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury in adults. LYRICA is indicated for the management of pain associated with fibromyalgia in adults. The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events ($\geq 5\%$ and twice the rate as that seen with placebo) in the recommended dose range of 150 mg/day to 600 mg/day in PHN and DPN patients were: dizziness (9.0-37.0%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%), and dry mouth (1.9-14.9%) and were dose related; in SCI patients: somnolence (41.4%), dizziness (24.3%), asthenia (15.7%), dry mouth (15.7%), edema (12.9%), constipation (12.9%), amnesia (10.0%), myasthenia (8.6%), amblyopia (8.6%), and thinking abnormal (8.6%); in fibromyalgia patients: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and

peripheral edema (6.1%). In LYRICA-treated fibromyalgia patients, the most commonly observed dose-related adverse events were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly observed adverse events in the PHN, DPN, SCI and fibromyalgia patients were usually mild to moderate in intensity. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 9% and 4% in DPN, 14% and 7% in PHN, 21% and 13% in SCI, and 20% and 11% in fibromyalgia. There was a dose-dependent increase in rate of discontinuation due to adverse events in DPN, PHN and fibromyalgia patients.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

There have been post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, and constipation) in patients, some without reported previous history/episode(s), during initial/acute and chronic treatment with LYRICA, primarily in combination with other medications that have the potential to produce constipation. Some of these events were considered serious and required hospitalization. In a number of instances, patients were taking opioid analgesics including tramadol. Caution should be exercised when LYRICA and opioid analgesics are used in combination, and measures to prevent constipation may be considered, especially in female patients and elderly as they may be at increased risk of experiencing lower gastrointestinal-related events.

Dosage reduction is required in patients with renal impairment (creatinine clearance < 60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.

Please see Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

† Please consult Prescribing Information for complete Dosage and Administration instructions.



Working together for a healthier world™

©2012 Pfizer Canada Inc. Kirkland, Quebec H9J 2M5

TM Pfizer Inc., used under license LYRICA © C.P. Pharmaceuticals International C.V., owner/Pfizer Canada Inc., Licensee

